Cubist Systematic Strategies LLC Sells 32,948 Shares of Dianthus Therapeutics, Inc. $DNTH

Cubist Systematic Strategies LLC trimmed its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 60.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,818 shares of the company’s stock after selling 32,948 shares during the quarter. Cubist Systematic Strategies LLC owned approximately 0.07% of Dianthus Therapeutics worth $396,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Walleye Capital LLC lifted its stake in Dianthus Therapeutics by 29.0% in the first quarter. Walleye Capital LLC now owns 106,931 shares of the company’s stock worth $1,940,000 after acquiring an additional 24,041 shares during the period. Candriam S.C.A. bought a new stake in Dianthus Therapeutics in the first quarter worth $4,510,000. Wellington Management Group LLP boosted its holdings in Dianthus Therapeutics by 12.7% in the first quarter. Wellington Management Group LLP now owns 67,982 shares of the company’s stock worth $1,233,000 after acquiring an additional 7,645 shares in the last quarter. American Century Companies Inc. boosted its holdings in Dianthus Therapeutics by 8.7% in the first quarter. American Century Companies Inc. now owns 47,817 shares of the company’s stock worth $867,000 after acquiring an additional 3,821 shares in the last quarter. Finally, Nuveen LLC bought a new stake in Dianthus Therapeutics in the first quarter worth $1,168,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Up 6.6%

DNTH opened at $37.90 on Thursday. The stock’s fifty day moving average is $22.28 and its two-hundred day moving average is $20.32. The company has a market capitalization of $1.22 billion, a P/E ratio of -11.66 and a beta of 1.46. Dianthus Therapeutics, Inc. has a 52 week low of $13.36 and a 52 week high of $38.25.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The firm had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. Equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

DNTH has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday. Wedbush upped their price target on Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an “outperform” rating in a research report on Thursday, August 21st. Guggenheim upped their price target on Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday. Robert W. Baird upped their price objective on Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, William Blair started coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an “outperform” rating for the company. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Buy” and an average price target of $60.67.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.